« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | Xgeva (also marketed as Prolia) |
| Generic Name: | denosumab |
| Code Name: | AMG162 |
| Company: | Amgen |
| FDA Clinical Phase: | 2 & 3 |
Description:
Prolia is a human monoclonal …
| Brand Name: | Doxil | |
| Generic Name: | doxorubicin HCl liposome injection | |
| Code Name: | ||
| Company: | Ortho Biotech | |
| FDA Clinical Phase: | 1,2, & 3 |
Description:
Doxil is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles.| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence …
| Brand Name: | Afinitor |
| Generic Name: | everolimus |
| Code Name: | RAD001 |
| Company: | Novartis |
| FDA Clinical Phase: | 1/2 |
Description:
Afinitor was approved by the FDA in March 2009 for the …
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Triphase Research and Development I Corp |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the …